A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard

BACKGROUND: We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk. METHODS AND FINDINGS...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Schmucker, Christine, Ehlken, Christoph, Agostini, Hansjuergen T., Antes, Gerd, Ruecker, Gerta, Lelgemann, Monika, Loke, Yoon K.
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2012
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3411814/
https://ncbi.nlm.nih.gov/pubmed/22880086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0042701
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares